Results 201 to 210 of about 41,693 (234)

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

Vaccine, 2012
Katia Pauwels
exaly  

ALCOHOL AND DRUGS AMONG MVA AND NON-MVA ADMISSIONS TO A REGIONAL TRAUMA UNIT

The Journal of Trauma: Injury, Infection, and Critical Care, 1990
B M Kapur, E Vingills, B McLellan, W Nelson, W-J Sheu   +4 more
openaire   +1 more source

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

Journal of Infectious Diseases, 2015
K J Ewer, Eleanor Berrie, Susanne Hodgson   +2 more
exaly  

2010 — An MVA seminar

Transportation, 1990
openaire   +1 more source

Albany MVA project.

2005
Edward B. Blanchard, Edward J. Hickling
openaire   +1 more source

Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses

Vaccine, 2018
Wei-Gang Hu, Les P Nagata, Ariane Volkmann   +2 more
exaly  

MVA Quadratic Forms and Geometry

2023
Matthias Fengler, Wolfgang Karl Härdle
openaire   +1 more source

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins

Vaccine, 2004
Gerd Sutter, Peter Jm Openshaw, Yasemin Suezer   +2 more
exaly  

Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

Virus Research, 2006
Dolores Rodríguez, Mariano Esteban
exaly  

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA

Vaccine, 1999
Stephen Whitehead, Bernard Moss, Linda S Wyatt   +2 more
exaly